Changing incentives to ACCELERATE drug development for paediatric cancer.

ABSTRACT:

Background

More effective incentives are needed to motivate paediatric oncology drug development, uncoupling it from dependency on adult drug development. Although the current European and North-American legislations aim to promote drug development for paediatrics and rare diseases, children and adolescents with cancer have not benefited as expected from these initiatives and cancer remains the first cause of death by disease in children older than one. Drug development for childhood cancer remains dependent on adult cancer indications and their potential market. The balance between the investment needed to execute a Paediatric Investigation Plan (PIP) in Europe and an initial Paediatric Study Plan (iPSP) in the US, coupled with the potential financial reward has not been sufficien

SUBMITTER: de Rojas T 

PROVIDER: S-EPMC10134303 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature